Title
The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions.

Permalink
https://escholarship.org/uc/item/119831zh

Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 17(1)

ISSN
1600-6135

Authors
Bruneval, P
Angelini, A
Miller, D
et al.

Publication Date
2017

DOI
10.1111/ajt.14112

Peer reviewed
The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions

P. Bruneval1,†, A. Angelini2,†, D. Miller3,†, L. Potena4, A. Loupy5,+, A. Zeevi6, E. F. Reed7, D. Dragun8, N. Reinsmoen9, R. N. Smith10, L. West11, S. Tebutt12, T. Thum13, M. Haas14, M. Mengel15, P. Revelo3, M. Fedrigo2, J. P. Duong Van Huyen5 and G. J. Berry16

1Paris Translational Research Center for Organ Transplantation & Department of Pathology, Hôpital Européen Georges Pompidou, Université Paris Descartes Médecine, Paris, France
2Department of Cardiac Thoracic and Vascular Sciences, University of Padua Medical School, Padua, Italy
3Intermountain Medical Center, University of Utah, Salt Lake City, UT
4Heart and Lung Transplant Program, University of Bologna, Academic Hospital S, Orsola-Malpighi, Italy
5Paris Translational Research Center for Organ Transplantation INSERM U970, Necker Hospital University Paris Descartes, Paris, France
6University of Pittsburgh Medical Center, Pittsburgh, PA
7Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA
8Berlin Institute of Health and Department of Nephrology and Critical Care Medicine, Charité Universitätsmedizin, Berlin, Germany
9Cedars-Sinai Medical Center, Los Angeles, CA
10Pathology Department, Massachusetts General Hospital, Boston, MA
11Alberta Transplant Institute and University of Alberta, Edmonton, Canada
12Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, BC, Canada
13IFB, Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany
14Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
15Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
16Department of Pathology, Stanford University, Stanford, CA
+Corresponding author: Alexandre Loupy, alexandreloupy@gmail.com
†These authors contributed equally.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody-mediated rejection (AMR) and small vessel arteriopathy. Specific topics included the strengths and limitations of the current rejection grading system, the central role of microvascular injury in AMR and approaches to semiquantitative assessment of histopathologic and immunophenotypic indicators, the role of AMR in the development of cardiac allograft vasculopathy, the important role of serologic antibody detection in the management of transplant recipients, and the potential application of new molecular approaches to the elucidation of the pathophysiology of AMR and potential for improving the current diagnostic system. Herein we summarize the key points from the presentations, the comprehensive, open and wide-ranging multidisciplinary discussion that was generated, and considerations for future endeavors.

Abbreviations: ACR, acute cellular rejection; AECVP, European Association for Cardiovascular Pathology; AMR, antibody-mediated rejection; CAV, cardiac allograft vasculopathy; DSA, donor-specific antibodies; EMB, endomyocardial biopsy; IAMC, intravascular activated mononuclear cells; ISHLT, International Society for Heart & Lung Transplantation

Received 17 July 2016, revised 30 September 2016 and accepted for publication 31 October 2016

Introduction

The XIIIth Banff meeting was held October 5–10, 2015 in Vancouver, British Columbia, Canada in conjunction with the Annual Scientific Meeting of the Canadian Society of
Transplantation. A total of 451 delegates from 28 countries attended the conference, including pathologists, immunologists, immunogeneticists, and transplant physicians and surgeons. Heart transplant diagnostics was covered as part of a dedicated session during the Banff conference. The main goal was to explore and enhance the common issues facing the different solid organ transplant groups, to identify new challenges in thoracic transplant diagnostics, and to foster a collaborative effort among transplant teams to address these unmet needs. The commonalities and challenges between kidney and heart transplant rejection was stressed during the meeting introduction by the program chairs G. Berry, MD and A. Angelini, MD. This provided a great opportunity to explore and for building an integrative network among the different specialties and solid organ transplant groups. The present report summarizes some of the outstanding issues in heart transplant diagnostics identified by the panel and members of the audience together with the main results presented by experts from centers from different parts of the world and summary from live discussions. Lastly, this report addresses proposals for future investigations to elucidate specific issues in heart transplantation (Table 1).

The Current Diagnosis System for Antibody-Mediated Rejection: Certainties and Uncertainties

Currently, the endomyocardial biopsy (EMB) serves as a primary diagnostic tool for the diagnosis of antibody-mediated rejection (AMR). The EMB permits the identification of AMR-induced tissue damage and the myocardial response to injury. The histopathological changes in AMR have been formally addressed in the working formulation for the pathologic diagnosis, grading, and reporting of cardiac AMR (1) under the auspices of the International Society for Heart & Lung Transplantation (ISHLT). Although the authors of this working formulation recognized that unresolved pathologic questions remain, the current grading paradigm represents a standardization of nomenclature, diagnostic criteria, and a reporting scheme to facilitate communication between pathologists and clinicians to promote future multicenter studies and serves as a foundation for pathologic and other research investigations.

Certainties

pAMR working formulation is a purely pathology-based approach relying on histopathology and immunohistochemistry: The main histopathologic feature of cardiac AMR is microvascular injury with accumulation of intravascular macrophages representing microvascular inflammation (Figure 1). As swollen endothelial cells and T-lymphocytes (2) are part of the spectrum of cells that can be present in the lumens of interstitial capillaries and venules in AMR and other processes, the descriptive term “activated mononuclear cells” is applied to indicate the difficulty in distinguishing the cellular components by routine staining alone. The immunophenotypic component requires multifocal/diffuse (>50%) C4d capillary endothelial deposition or ≥10% CD68-positive intravascular macrophages within capillaries or venules. The grading of AMR is based on the combination of morphologic and immunopathologic findings as follows: pAMR 0 negative for pathologic AMR when both histology and immunohistochemistry are negative; pAMR 1 (H+) when histopathologic findings are present and immunohistochemistry negative; pAMR 1 (I+) when histopathologic findings are negative and immunohistochemistry C4d and/or CD68 is positive; pAMR 2 or pathologic AMR when both histopathologic and immunopathologic findings are present; pAMR 3 or severe pathologic AMR: immunopathologic findings and myocyte necrosis, microvascular thrombosis, interstitial hemorrhage and/or polymorphic inflammation are present.

**Table 1:** Key questions to address in the setting of heart transplant diagnostics identified by the panel

| Microcirculation inflammation | Chronic antibody-associated allograft damage |
|-------------------------------|--------------------------------------------|
| Antibody detection in cardiac AMR |
| Molecular approaches in heart TX |

Ab, antibody; ACR, acute cellular rejection; AMR, antibody-mediated rejection; CAV, cardiac allograft vasculopathy; ISHLT, The International Society for Heart & Lung Transplantation; MI, microvascular injury; pAMR, pathologic antibody-mediated rejection; TX, transplant.
It is a pathologic grading scheme independent of clinical and serologic data: One of the main conclusions of the 2010 ISHLT consensus meeting on AMR (3) was that pAMR would be a purely pathologic diagnosis akin to the diagnosis of acute cellular rejection (ACR), without the requirements of donor-specific antibodies (DSA) and allograft dysfunction.

Currently, it is a diagnostic working formulation rather than a predictive or prognostic scheme: Except for pAMR3 or severe AMR that is usually associated with marked cardiac dysfunction, the other AMR grades (pAMR0 to pAMR2) have not been correlated with DSA levels, immediate prognosis, or clinical AMR in prospective studies and importantly, have not yet established treatment thresholds (4).

It is a consensus working formulation: pAMR working formulation resulted from the cumulative work of four consensus meetings: Allograft Pathology Conference in Banff 2009 and ISHLT meetings in Chicago, IL in 2010, San Diego, CA 2011, and Prague, Czech Republic 2012. Among its designated purposes will be a standardized format for reporting AMR in institutional programs and for multicenter studies (1,4).

It is quite easy to use and learn: It has been validated by a reproducibility study on digitalized slides hosted on a web site testing 24 AMR-positive EMBs among a panel of 13 pathologists (1). A tutorial for pAMR learning is now available at http://scvp.net/amr/index.html.

pAMR working formulation is supported by scientific evidences: pAMR grades are correlated with DSA and mTOR pathway activation in endothelial cells (5) and a limited number of retrospective clinical studies (6).

Uncertainties
Although the pAMR working formulation is now widely used as a diagnostic tool for cardiac AMR, there are limitations that will need to be addressed in future studies. These could include refinement of diagnostic thresholds, morphologic criteria, and importantly, clinicopathologic correlations to determine indications for therapeutic intervention.
The morphologic basis of pAMR, intravascular activated mononuclear cells (IAMC) and positive C4d and/or CD68 immunohistochemistry will require quantitative assessment: The threshold for which IAMC are considered significant for the possibility of AMR in hematoxylin and eosin (H&E)-stained sections has not been formally established. In the majority of cases the morphologic changes are diffusely present throughout the biopsy pieces (1). The clinical significance of focal or patchy histopathologic changes, while uncommon, is not understood. The establishment of a numeric threshold will require a formal study. The immunopathologic assessment of the thresholds for C4d and CD68 at 50% and 10%, respectively, were established by agreement of the participants in the working formulation. These parameters will need validation to better characterize the morphological diagnosis of AMR and establish a clinically relevant grading system.

The application of pAMR working formulation can present technical challenges: A major component of pAMR is the presence of mononuclear cells within the lumens of interstitial capillaries. The intravascular location of cells can be difficult to recognize by routine histology or by immunohistochemistry for a variety of technical and interpretative reasons as discussed in the working formulation (1). Double labeling with an endothelial marker (CD31 or CD34) has limited availability in many practices. An expanded repertoire of antibodies including PU.1 (BD Bioscience, San Jose, CA) may be helpful to distinguish intravascular from extravascular locales. The true nature of IAMC may not be apparent by routine H&E staining as the possible cell types include endothelial cells, lymphocytes, and macrophages among others. Phenotyping of the IAMC by immunohistochemistry is mandatory since only macrophages are assessed in the evaluation of AMR (2). The presence of intravascular lymphocytes and occasional macrophages not uncommonly accompany the pAMR.

This consensus reflected the current state of knowledge and experience in the morphology of AMR at that time, but the group was aware of the many questions left open such as (i) evaluating IAMC is at present purely binary (presence or absence); (ii) in many cases, distinguishing between intravascular macrophages and swollen endothelial cells or other cell types, i.e. lymphocytes, is difficult if the phenotype of intracapillary cells is not routinely assessed by immunohistochemistry; (iii) recognizing the predominant pattern of intravascular versus extravascular localization of inflammatory cells may be challenging. This distinction is important as it is utilized to differentiate ACR from AMR.

A recent pilot study (2) from the European Association for Cardiovascular Pathology (AECVP) focused on the inflammatory burden (IB) in 35 cases of pAMR1 or pAMR2 cases without significant ACR (ISHLT 0 or ≤1R), using an antibody panel consisting of the complement C4d, pan-T-cell CD3-T, pan-B-cell CD20, macrophage CD68, and a plasma cell marker, CD138. The primary findings in this study included the following: (i) the number of intracapillary inflammatory cells vary greatly between AMR cases (even in cases classified in the same categories); (ii) macrophages are not the sole cell type present in AMR, as a variable proportion of T-cells can be present and fewer B-cells and plasma cells;
Figure 2: Microcirculation inflammation in cardiac AMR. (A) CD68-positive intravascular mononuclear cell in several capillaries reflecting their monocyte-macrophage lineage. In this field, most of the labeled cells are clearly intravascular. CD68 immunohistochemistry; original ×40. (B) CD3-positive intravascular mononuclear cell in capillaries reflecting that T-lymphocytes are a significant cell component of the intravascular activated mononuclear cells in AMR. CD3 immunohistochemistry; original ×40. (C) Double labeling using an endothelial marker (CD31) in red and a T-lymphocyte marker (CD3) in brown demonstrating the intravascular location of the CD3-positive cells. This pattern is different from the T-lymphocyte riming around capillaries and venules in cellular rejection. Double CD31-CD3 immunohistochemistry; original ×40. (D–F) Low-magnification views showing different intensities of the extension of the microcirculation inflammation in biopsies: D– minimal; E– focal; F– diffuse. Hematoxylin and eosin (H&E) stain; original ×10. (G–I) Higher magnification views showing different patterns of accumulation of the intravascular activated mononuclear cells (IAMC) in biopsies: G– rare IAMC; H– some IAMC; I– many IAMC forming intravascular plug. H&E stain; original ×20. AMR, antibody-mediated rejection.

Figure 3: Spectrum of cardiac allograft vasculopathy (from epicardial arteries to myocardial capillaries). (A) Allograft epicardial coronary artery showing intimal and adventitial inflammation (hematoxylin and eosin [H&E], ×100). (B) Allograft epicardial coronary artery showing intimal fibrosis with shallow fibrin thrombus at the luminal aspect and some entrapped fibrin deeper in the intimal wall (arrows) (H&E, ×20). (C) Allograft epicardial coronary artery with less intimal thickening but dramatic adventitial lymphoid aggregate (asterisk) (H&E, ×20). (D) Allograft epicardial coronary artery showing advanced narrowing with a slit-like lumen; there is very little outward remodeling of the vessel wall (H&E, ×40). (E) Allograft endomyocardial biopsy photomicrograph after computer-assisted image analysis for capillary density. This case showed reduced capillaries (CD34 stain, ×200) (MVD, microvascular density). (F) Allograft endomyocardial biopsy photomicrograph after computer-assisted image analysis for capillary density. This case showed preserved capillary density (CD34 stain, ×200). (G) and (H) Electron photomicrographs of allograft myocardium showing an interstitial capillary with basement membrane multilayering (arrows) (original ×4000 and ×10 000).
(iii) extravascular pericapillary inflammatory cells consisting of both lymphocytes and macrophages are frequently observed in the presence of intracapillary hypercellularity.

The authors promoted the need for further studies to address these issues in large collaborative multicenter studies. Some interesting points addressed by the study
warrant highlighting: (i) the heterogeneity of IB in cardiac pAMR in general, and in early and late or very late pAMR; (ii) the presence of inflammatory cell gradients and heterogeneous cell profiles in pAMR grades; (iii) the complex interplay between cellular- and antibody-mediated immunological processes, with the reciprocal influence of ACR and AMR, and consequently the issue of mixed ACR-AMR rejection. The ISHLT working group proposed to address the issue of mixed rejection in subsequent multicenter projects. At the 2016 Washington ISHLT Meeting, the Pathology Council proposed that the IB study be extended to a wider multicenter study to address these points and to focus on mixed rejection in more detail.

Another issue discussed at Banff 2015 was the assessment of MI using a semiquantitative histologic grading system. In kidney transplantation, a semiquantitative histologic evaluation of MI that combines glomerulitis and peritubular capillaritis scores is now part of the Banff schema for the diagnosis of renal AMR. High-grade MI has been associated with worse renal allograft outcome in some studies (11). The French transplant group reported its preliminary data applying a semiquantitative grading scheme to assess MI severity. The score incorporates both the extent (percentage of the specimen involved) and pattern (maximum number of inflammatory cells in the most affected capillaries or venules) of IAMC. The preliminary results showed an association between the MI grade and AMR disease activity measured by molecular analysis. During the group discussion it was recognized that the MI grading scheme should be further evaluated in a multicenter study to address its reproducibility and correlation with allograft outcomes. At the subsequent 2016 ISHLT meeting in Washington, DC, the Pathology Council proposed that the project on histologic MI grading be included in a multicenter study, with particular attention to the issues of sensitivity and specificity of histologic aspects in MI, inter-, and intraobserver reproducibility, and correlation with current AMR histologic criteria, clinical, and immunologic findings and ultimately with outcome data.

Assigning Specific Phenotypes of Alloimmune-Mediated Vascular Injury (Figure 3)

The recognition of AMR in cardiac allografts has evolved over the last quarter century (12). Originally it was recognized as a cause of early allograft dysfunction but late-onset AMR is now encountered. Furthermore, asymptomatic AMR has been reported, although the clinical significance remains controversial (13–15). The natural history of AMR and specifically the cumulative effects of repetitive AMR episodes on allograft function and survival have been addressed in a limited number of studies (16).

AMR affects the endothelium throughout the heart and the morphologic manifestations vary according to vessel caliber. The epicardial coronary and penetrating arteries show alterations termed “cardiac allograft vasculopathy (CAV)”. The small vessels and microcirculation are also affected, initially manifesting as MI with IAMC (1) with progression to loss of capillaries per unit area (microvascular density) (17) and structural changes (thickening) (18).

Morphologic manifestations of CAV in epicardial and myocardial muscular arteries are both inflammatory and proliferative in nature. Inflammation may be limited to the intimal layer (endothelialitis or intimitis) or extend transmurally. Shallow nonocclusive thrombus accompanies the inflammatory lesion in some cases. The proliferative lesions are confined to the intimal layer, but differ from native atherosclerosis by their concentric distribution, limited lipid deposition, and absence of outward remodeling of the media and adventitia (19,20).

CAV has been associated with AMR in published studies for more than two decades now (21), but the stringency of that association as well as the apparent correlation between CAV and other non-AMR factors suggests a more complex interplay (21–24). At the capillary level, the classic features of AMR are endothelial swelling and accumulation of intravascular macrophages. Complement activation, characterized by C3d and C4d deposition in tissue sections, is a key component of AMR, but may not be demonstrable in every case and is then captured in the AMR grading scheme as pAMR 1(H+) (1). This may be explained, in part, by the decrement in myocardial capillary density and morphologic alteration of capillaries manifesting as multilayering of their supporting basement membranes in cases of repetitive microvascular injury (25).

Much work remains to be performed to unravel the immunobiology, morphology, and pathophysiology of AMR’s influence on the cardiac vasculature from the epicardial arteries to the interstitial capillaries. While many studies have highlighted a correlation, other studies have not shown a link between these processes (26). Additional clinical and pathologic studies along with more robust animal models will be needed to clarify the morphologic, immunopathologic, serologic, and molecular components of AMR. The current diagnostic criteria and grading scheme serve as an initial platform for this work. As emphasized by the working formulation of the ISHLT, there will be a need to reconvene in the future to reassess the concepts and approaches to the diagnosis of AMR. Lastly, there is now a standardization of nomenclature for the angiographic diagnosis and classification of CAV, but there remains a need for uniform pathologic terminology. The renal transplant community has established morphologic criteria for “acute” and “chronic” AMR (27). In the cardiac literature the terms are often
long-term cardiac allograft survival (23,30). DSA testing progression to cardiac allograft vasculopathy and reduced AMR (3,16,28,29). Furthermore, DSA are associated with survival is lower in recipients with DSA at the time of specific HLA antibodies (DSA) and cardiac transplant that cardiac AMR diagnosis is associated with donor- or non-HLA antibodies. Numerous studies have shown evaluation to identify the causative agent, namely, HLA currently, most patients with suspected AMR will undergo assessment of the patient is heavily underscored. Cur- bly role and importance of clin- bodies (1). That said, the vital role and importance of clin- and/or presence of donor-specific HLA or non-HLA anti- ing the additional features of clinical graft dysfunction and nonimmune mechanisms may play an important mechanistic role in these changes. “Chronic antibody- associated allograft damage” was proposed as a term appropriately encompassing the changes described herein. More precise terminology and definitions will be needed to establish databases and design studies exam- ining “early-onset acute,” “late-onset acute,” “recur- rent,” “persistent,” and “chronic” AMR.

The Place of Antibody Detection in AMR Assessment in Heart Transplantation

The current ISHLT grading system for cardiac AMR is based exclusively on pathologic evidence, without requiring the additional features of clinical graft dysfunction and/or presence of donor-specific HLA or non-HLA anti- bodies (1). That said, the vital role and importance of clinical information and serologic data in the overall assessment of the patient is heavily underscored. Current- ly, most patients with suspected AMR will undergo evaluation to identify the causative agent, namely, HLA or non-HLA antibodies. Numerous studies have shown that cardiac AMR diagnosis is associated with donor-specific HLA antibodies (DSA) and cardiac transplant survival is lower in recipients with DSA at the time of AMR (3,16,28,29). Furthermore, DSA are associated with progression to cardiac allograft vasculopathy and reduced long-term cardiac allograft survival (23,30). DSA testing shows outstanding sensitivity and negative predictive value for biopsy-diagnosed AMR in both adult and pedi- atric cardiac transplant recipients (31). In posttransplant care, quantitative DSA should be an essential component in the surveillance for AMR. Moreover, the presence of mixed AMR and ACR concurrently (8) may be explained by the fact that antibodies mediate leukocyte recruitment to the allograft via IgG-Fc receptor-mediated effector functions (32). Table 2 summarizes outstanding questions identified and potential recommendations made by the Ab expert panel. As the immunologic testing and interpretation of test results become more standardized across transplant centers, some investigators have raised the issue of reintroducing HLA DSA and non-HLA anti- body testing information for use in the diagnosis of AMR and for risk assessment of persistent AMR and CAV (3). Whether there is currently sufficient standardization and consensus among immunologists and clinicians is contro- versial and awaits future investigation, consensus analy- sis, and debate.

New advances in antibody testing by introduction of multiplex-bead array assays have revolutionized the field and significantly improved the sensitivity and precision of circulating DSA detection. The benefits and limitations of the solid-phase assay using single antigen beads have been captured in many reviews (33–39). In Table 3 the American Society for Histocompatibility and Immuno- genetics HLA panel experts describe problems that may impact test interpretation and provide potential solutions to avoid false positive or incomplete results that may influence patient management. The continuous dialogue between the clinical laboratory and clinicians is the key to provide the most accurate information. The clinical impact of non-HLA-specific antibodies either alone or

| Questions | Recommendations | Definitions |
|-----------|-----------------|-------------|
| What is the optimum timing of DSA testing posttransplantation? | Stratify the patients based on risk for AMR and monitor: • High and intermediate risk with each biopsy early posttransplant, 3, 6, 9, 12 months first year and yearly if no clinical indication. • Low-risk minimum 3, 6, 12 months, yearly after and anytime clinically indicated | • High risk: presence of DSA at the time of transplant • Intermediate risk: presence of DSA in historical samples • Low risk: no DSA detected |
| When DSA should be treated? | • Increased level (titer and MFI) of persistent DSA should be biopsied to rule out subclinical rejection. • Strong correlation of persistent DSA with graft dysfunction | • Level DSA levels assessed by MFI strength and/or titration of sera • Persistent DSA: presence of DSA in serial samples • Transient DSA: Presence of DSA only in one sample |
| Should DSA testing be performed with diagnosis of pAMR? | • Testing for DSA presence and level (HLA and non-HLA) should be performed to: o correlate with severity of pAMR o assess efficacy of treatment | |

Ab, antibody; AMR, antibody-mediated rejection; DSA, donor-specific antibodies; MFI, mean fluorescence intensity.
Bruneval et al

Table 3: Prospects for implementing HLA-Ab detection into the AMR classification in cardiac transplantation: limitations and potential solutions

| Problem                                      | Interpretation                                                                 | Resolution                                                                 |
|----------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| HLA-Ab to denatured antigens                 | False positive results: HLA-Ab to cryptic epitopes, clinically irrelevant        | Repeat testing after acid treatment of SAB; surrogate crossmatch            |
| Intrinsic and extrinsic factors inhibiting the SAB assay | False low MFI or negative results: due to inhibition of SAB assay                    | Dilution of sera pretesting, adsorption, inhibition of C1q, addition of EDTA, heat treatment to remove and uncover the real reactivity |
| Low MFI on SAB resulting in higher reactivity using cellular targets | False low MFI: DSA to a shared target present on multiple beads                    | Adequate analysis of specific DSA epitope                                    |
| Using MFI to evaluate level and strength of DSA for risk stratification | Low or high MFI level of DSA may not correlate with risk of AMR, or response to treatment following antibody removal therapies | Modified SAB assay to distinguish between complement and noncomplement binding DSA and determining titer of DSA (serial dilutions of patient sera) |

Ab, antibody; AMR, antibody-mediated rejection; DSA, donor-specific antibodies; EDTA, ethylenediamine tetraacetic acid; MFI, mean fluorescence intensity; SAB, single-antigen bead.

together with DSA recently has been an intense area of research in solid organ transplantation (40,41). Newly developed enzyme-linked immunosorbent assay solid-phase assays have allowed a reliable means of detecting antibodies to the G protein-coupled receptors, angiotensin-II type 1 receptor (AT1R) and endothelin type A receptor (ETAR). These reagents together with the availability of proficiency testing programs have allowed their implementation in testing for clinical transplantation. Elevated levels of AT1R and ETAR have been associated with early onset of microvasculopathy as well as with AMR and ACR (42). Furthermore, freedom from AMR and/or ACR was observed to be significantly decreased when both de novo DSA and increased AT1R antibodies levels were considered (43). A growing body of evidence supports the role of alloimmune and autoimmune mechanisms involving antibodies directed against non-HLA antigens in transplant allograft damage (44–46).

Need for Complementary Tissue Molecular Approaches

The ISHLT working formulation has taken important steps to improve the pathological diagnosis and uniform reporting of AMR. The panel and live discussion at the Banff conference discussed some of the issues that remain unresolved such as regarding the pathophysiology of heart rejection and how activity, injury degree, and stage could be improved. As discussed in an earlier section, the emerging role of molecular diagnostics is a potential avenue to further our mechanistic understanding of ACR and AMR, to help refine our current diagnostic categories and elucidate thresholds for therapeutic intervention. Molecular diagnostics has been utilized in renal transplantation to identify the subset of C4d-negative patients with AMR. There is currently limited but evolving data in the cardiac AMR arena. Preliminary data from the Paris-Bologna-Edmonton collaboration were presented showing the potential of gene expression in EMB to map the molecular architecture of AMR and its correlation with disease activity. The commonalities between cardiac and kidney transplant rejection suggests the molecular microscope as an important approach that should be actively investigated by transplant research groups. The panel cautioned about the need for a comprehensive clinical and pathologic detail including state-of-the-art DSA assessment using sensitive assays and accepted thresholds such as mean fluorescence intensity before a specific set of genes could be correlated to specific allograft injury phenotypes. In this setting, it was also suggested that as there is a morphologic and immunophenotypic spectrum for AMR, it is unlikely that a single gene will be specific and that this very complex undertaking will require transcriptomics data based on methodical approaches such as classifiers, machine learning, etc. Finally, the panel supported and encouraged collaborations within centers and promoted multicenter studies.

Summary and Future Directions

The diagnostic, therapeutic, and mechanistic landscapes of allograft rejection have evolved and changed dramatically over the last 25 years. The incidence of clinically significant ACR has diminished in most transplant centers, with 5% to 15% of EMB being positive for T cell-mediated rejection of the total of EMB performed in the first year posttransplant. Cardiac allograft vasculopathy remains the persistent impediment to long-term allograft and patient survival. While the angiographic findings and corresponding histopathologic features have been well known for many decades, the immunobiology continues to evolve through clinical and animal studies. The role of the EMB has emerged as a useful investigative tool. It
was once thought that the myocardial changes were static and merely reflected effects of larger epicardial disease; however, the focus has now shifted to the microvascular changes in the capillaries, venules, and arterioles and their role in the clinical and pathophysiological consequences of CAV. There is a need for more precise terminology, definitions, and classifications of the changes at the microvascular level and uniformity in approaches, morphometrics, and immunohistochemical analysis.

The role of AMR in the initiation of allograft dysfunction and the development of CAV has also matured. The working formulation for the diagnosis and reporting of AMR has now been utilized for less than 5 years and the results from single-center studies are limited. Its original aim to provide a framework for clinical and investigative endeavors should remain, with the intended goal to re-evaluate its functionality in the future based on published data. That said, the rapidly expanding influence of proteomics, transcriptomics, and other molecular diagnostic approaches will likely illuminate and clarify our current concepts.

The overlap of clinical, histopathologic, and immunophenotypic features of AMR in the different solid organ transplant groups encourages the multidisciplinary and transdisciplinary endeavors of the Banff Conference. Much can be learned from each group. In acute renal AMR, like its cardiac counterpart, microvascular injury is centered on the microvasculature such as the peritubular capillary injury and the glomerulitis resulting in endothelial alterations, interstitial edema, and in severe cases, vascular thrombosis and fibrinoid necrosis (27). The cardiac morphologic spectrum has been described in detail in earlier sections of this report. The acute manifestations of AMR in the liver allograft are evolving but include endothelial swelling in the portal veins, venulitis, and capillaritis with hepatocyte ballooning and cholestasis (47). Chronic AMR has been defined and criteria have been enumerated in the renal allograft (27). They include glomerular double contours, peritubular capillary multilayering of basement membranes, interstitial fibrosis, tubular atrophy, and intimal proliferation of arteries. In the liver interface hepatitis, lobular inflammation, periportal and sinusoidal fibrosis, and vasculopathy have been described (47). The cardiac allograft currently does not have a formal “chronic AMR” designation, but there is an overlap of findings with the kidney and liver. These similarities provide an impetus and directions for further investigations.

This rich array between the different solid organ groups provides a multitude of directions and opportunities for transdisciplinary collaborations. The molecular discoveries in kidney AMR, including the category of C4d-negative AMR (48), are currently being evaluated in some cardiac groups. Together with future clinical, pathologic, serologic, and other discoveries, these molecular data may help to clarify clinical, therapeutic, predictive, and prognostic information. Ultimately, the goal of overcoming transplant vasculopathy and graft loss in the different transplant groups may yet be realized. To this end, collaborations among transplant groups and societies will expedite these goals.

Acknowledgments

We would like to acknowledge the instrumental support from the Roche Organ Transplantation Research Foundation (ROTRF) Grant 608390948 awarded to Dr. Kim Solez, which allowed establishment of the Banff Foundation for Allograft Pathology. The joint 2015 Banff and Canadian Transplant Society meeting acknowledges the receipt of sponsorship from Astellas, Alexion, Novartis, One Lambda, Renal Pathology Society, American Society of Transplantation, Wiley, Qiagen, Canadian Institute for Health Research, Immucor, Bridge to Life, Organ Recovery Systems, Transplant Connect, Glycorex Transplantation, Transpath Inc., and the University of Alberta.

Disclosure

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

References

1. Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013; 32: 1147–1162.
2. Fedrigo M, Leone O, Burke MM, et al. Inflammatory cell burden and phenotype in endomyocardial biopsies with antibody-mediated rejection (AMR): A multicenter pilot study from the AECVP. Am J Transplant 2015; 15: 526–534.
3. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252–269.
4. Colvin MM, Cook JL, Chang P, et al. Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: A scientific statement from the American Heart Association. Circulation 2015; 131: 1608–1639.
5. Tible M, Loupy A, Vernerey D, et al. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung Transplant 2013; 32: 769–776.
6. Hammond ME, Reveo MP, Miller DV, et al. ISHLT pathology antibody mediated rejection score correlates with increased risk of cardiovascular mortality: A retrospective validation analysis. J Heart Lung Transplant 2016; 35: 320–325.
7. Fedrigo M, Feltrin G, Poli F, et al. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. J Heart Lung Transplant 2013; 32: 404–409.
8. Kfouri AG, Miller DV, Snow GL, et al. Mixed cellular and antibody-mediated rejection in heart transplantation: In-depth pathologic and clinical observations. J Heart Lung Transplant 2016; 35: 335–341.

9. Lepin EJ, Zhang Q, Zhang X, et al. Phosphorylated S6 ribosomal protein: A novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6: 1560–1571.

10. Li F, Wei J, Valenzuela NM, et al. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts. J Heart Lung Transplant 2015; 34: 580–587.

11. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168–1179.

12. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005–2011). J Heart Lung Transplant 2011; 30: 601–611.

13. Berry GJ. Antibody-mediated rejection of the cardiac allograft: Where do we stand in 2012? Curr Opin Organ Transplant 2012; 17: 303–308.

14. Chih S, Tinckam KJ, Ross HJ. A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant 2013; 13: 1069–1074.

15. Kfouri AG, Snow GL, Budge D, et al. A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012; 31: 46–51.

16. Loupy A, Toquet C, Rouvier P, et al. Late failing heart allografts: Pathology of cardiac allograft vasculopathy and association with antibody-mediated rejection. Am J Transplant 2016; 16: 111–120.

17. Revelo MP, Miller DV, Stehlik J, et al. Longitudinal evaluation of microvessel density in survivors vs. nonsurvivors of cardiac pathologic antibody-mediated rejection. Cardiovasc Pathol. 2012; 21: 445–454.

18. Hiemann NE, Wellhöfer E, Knoasla C, et al. Prognostic impact of microvasculopathy on survival after heart transplantation: Evidence from 9713 endomyocardial biopsies. Circulation 2007; 116: 1274–1282.

19. Lu WH, Palatinik K, Fishbein GA, et al. Diverse morphologic manifestations of cardiac allograft vasculopathy: A pathologic study of 64 allograft hearts. J Heart Lung Transplant 2011; 30: 1044–1050.

20. Rahman M, Cruz RP, Granville DJ, et al. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801–815.

21. Hammond EH, Yowell RL, Price GD, et al. Vascular rejection and its relationship to allograft coronary artery disease. J Heart Transplant. 1992; 11 (Pt 2): S111–S119.

22. Irving CA, Carter V, Gennery AR, et al. Effect of persistent versus transient donor-specific HLA antibodies on graft outcomes in pediatric cardiac transplantation. J Heart Lung Transplant 2015; 34: 1310–1317.

23. Loupy A, Cazes A, Guillermain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant 2011; 11: 1478–1487.

24. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant 2009; 28: 417–422.

25. Hammond EH, Yowell RL. Ultrastructural findings in cardiac transplant recipients. Ultrastruct Pathol. 1994; 18: 213–220.

26. Abu-Qaoud MS, Stoeletniy LN, Chen D, et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. Transplantation 2012; 94: 965–970.

27. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272–283.

28. Ho EK, Vlad G, Vasilèscu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011; 72: 5–10.

29. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153–159.

30. Tran A, Fivler D, Huang R, et al. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation. J Heart Lung Transplant 2016; 35: 87–91.

31. Ware AL, Malmberg E, Delgado JC, et al. The use of circulating donor specific antibody to predict biopsy diagnosis of antibody-mediated rejection and to provide prognostic value after heart transplantation in children. J Heart Lung Transplant 2016; 35: 179–185.

32. Thomas KA, Valenzuela NM, Reed EF. The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection. Trends Mol Med 2018; 21: 319–329.

33. Eckels DD, Stehlik J, Kfouri AG. The detection and role of circulating antibodies in rejection. Curr Opin Organ Transplant 2013; 18: 589–594.

34. Haarberg KM, Tambur AR. Detection of donor-specific antibodies in kidney transplantation. Br Med Bull 2014; 110: 23–34.

35. Konvalinka A, Tinckam K. Utility of HLA antibody testing in heart transplantation. J Am Soc Nephrol 2015; 26: 1489–1502.

36. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19–47.

37. Tambur AR, Herrera ND, Haarberg KM, et al. Assessing antibody strength: Comparison of MFI, C1q, and titer information. Am J Transplant 2015; 15: 2421–2430.

38. Tyau DB. New approaches for detecting complement-fixing antibodies. Curr Opin Organ Transplant 2012; 17: 409–415.

39. Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013; 32: 98–105.

40. Dragun D, Muller DN, Bresan JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558–569.

41. Reinsmoen NL, Lai CH, Heidecke H, et al. Anti-angiotensin II type 1 receptor antibodies associated with antibody-mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473–1477.

42. Hiemann NE, Meyer R, Wellhöfer E, et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919–924.

43. Reinsmoen NL, Lai CH, Mirocha J, et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 2014; 97: 595–601.
44. Dragun D. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation. Transplantation 2008; 86: 1019–1025.
45. Dragun D, Catar R, Kusch A, et al. Non-HLA-antibodies targeting Angiotensin type 1 receptor and antibody mediated rejection. Hum Immunol 2012; 73: 1282–1286.
46. Dragun D, Catar R, Philippe A. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. Kidney Int 2016; 90: 280–288.
47. Demetris AJ, Bellamy C, Hubscher SG, et al. 2016 Comprehensive update of the Banff working group on liver allograft pathology: Introduction of antibody-mediated rejection. Am J Transplant. doi: 10.1111/ajt.13909 [Epub ahead of print].
48. Sis B, Jhangri GS, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9: 2312–2323.